Do analysts recommend XBIT or NAGE?

Niagen Bioscience has a consensus target price of $10.50, indicating a potential upside of 209.73%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00

Do analysts recommend XBIT or GALT?

Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 214.29%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galectin Therapeutics 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better earnings & valuation, XBIT or GALT?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.32 N/A Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A

Is XBIT or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat XBiotech's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -26.10% -25.06% Galectin Therapeutics N/A N/A -164.69%

Do analysts recommend CLLS or XBIT?

Cellectis presently has a consensus target price of $7.00, indicating a potential upside of 150.00%. Given Cellectis' stronger consensus rating and higher possible upside, analysts plainly believe Cellectis is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectis 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CLLS or XBIT more profitable?

XBiotech has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. XBiotech's return on equity of -26.10% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -89.51% -80.66% -20.51% XBiotech N/A -26.10% -25.06%

Do analysts prefer ALXO or XBIT?

ALX Oncology currently has a consensus price target of $4.60, indicating a potential upside of 127.72%. Given ALX Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe ALX Oncology is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ALXO or XBIT?

XBiotech is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A XBiotech N/A N/A -$45.54M -$1.32 N/A

Is ALXO or XBIT more profitable?

XBiotech's return on equity of -26.10% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% XBiotech N/A -26.10% -25.06%

Do analysts rate XBIT or SRZN?

Surrozen has a consensus target price of $42.00, indicating a potential upside of 93.37%. Given Surrozen's stronger consensus rating and higher possible upside, analysts plainly believe Surrozen is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Surrozen 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is XBIT or SRZN more profitable?

XBiotech has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat XBiotech's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -26.10% -25.06% Surrozen -4,810.50% N/A -154.08%

XBiotech (XBIT) Competitors

$2.27 +0.03 (+1.34%)

Closing price 07/22/2026 04:00 PM Eastern

Extended Trading

$2.28 +0.01 (+0.53%)

As of 08:40 AM Eastern

Compare

XBIT vs. NAGE, GALT, CLLS, ALXO, and SRZN

Should you buy XBiotech stock or one of its competitors? MarketBeat compares XBiotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XBiotech include Niagen Bioscience (NAGE), Galectin Therapeutics (GALT), Cellectis (CLLS), ALX Oncology (ALXO), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry.

How does XBiotech compare to Niagen Bioscience?

XBiotech (NASDAQ:XBIT) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Niagen Bioscience has a consensus target price of $10.50, indicating a potential upside of 209.73%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Niagen Bioscience has a net margin of 14.29% compared to XBiotech's net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Niagen Bioscience	14.29%	22.68%	16.23%

55.7% of XBiotech shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 30.8% of XBiotech shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Niagen Bioscience has higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Niagen Bioscience	$129.42M	2.09	$17.38M	$0.21	16.14

In the previous week, Niagen Bioscience had 2 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Niagen Bioscience and 0 mentions for XBiotech. Niagen Bioscience's average media sentiment score of 0.38 beat XBiotech's score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
XBiotech	Neutral
Niagen Bioscience	Neutral

XBiotech has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market.

Summary

Niagen Bioscience beats XBiotech on 14 of the 16 factors compared between the two stocks.

How does XBiotech compare to Galectin Therapeutics?

XBiotech (NASDAQ:XBIT) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

55.7% of XBiotech shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 30.8% of XBiotech shares are held by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Galectin Therapeutics' return on equity of 0.00% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Galectin Therapeutics	N/A	N/A	-164.69%

Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 214.29%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galectin Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Galectin Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 1 mentions for Galectin Therapeutics and 0 mentions for XBiotech. XBiotech's average media sentiment score of 0.00 beat Galectin Therapeutics' score of -0.68 indicating that XBiotech is being referred to more favorably in the media.

Company	Overall Sentiment
XBiotech	Neutral
Galectin Therapeutics	Negative

XBiotech has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Galectin Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

Summary

Galectin Therapeutics beats XBiotech on 8 of the 13 factors compared between the two stocks.

How does XBiotech compare to Cellectis?

Cellectis (NASDAQ:CLLS) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Cellectis presently has a consensus target price of $7.00, indicating a potential upside of 150.00%. Given Cellectis' stronger consensus rating and higher possible upside, analysts plainly believe Cellectis is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XBiotech has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. XBiotech's return on equity of -26.10% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
XBiotech	N/A	-26.10%	-25.06%

63.9% of Cellectis shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 30.8% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

XBiotech has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.53	-$67.59M	-$0.67	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

In the previous week, Cellectis had 2 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Cellectis and 0 mentions for XBiotech. Cellectis' average media sentiment score of 0.45 beat XBiotech's score of 0.00 indicating that Cellectis is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectis	Neutral
XBiotech	Neutral

Cellectis has a beta of 2.88, meaning that its stock price is 188% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Summary

Cellectis beats XBiotech on 11 of the 16 factors compared between the two stocks.

How does XBiotech compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

XBiotech's return on equity of -26.10% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
XBiotech	N/A	-26.10%	-25.06%

XBiotech is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 21.0% of ALX Oncology shares are held by company insiders. Comparatively, 30.8% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, ALX Oncology had 2 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for ALX Oncology and 0 mentions for XBiotech. ALX Oncology's average media sentiment score of 0.51 beat XBiotech's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
ALX Oncology	Positive
XBiotech	Neutral

ALX Oncology currently has a consensus price target of $4.60, indicating a potential upside of 127.72%. Given ALX Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe ALX Oncology is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ALX Oncology has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Summary

ALX Oncology beats XBiotech on 7 of the 13 factors compared between the two stocks.

How does XBiotech compare to Surrozen?

XBiotech (NASDAQ:XBIT) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

In the previous week, Surrozen had 2 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Surrozen and 0 mentions for XBiotech. Surrozen's average media sentiment score of 0.65 beat XBiotech's score of 0.00 indicating that Surrozen is being referred to more favorably in the news media.

Company	Overall Sentiment
XBiotech	Neutral
Surrozen	Positive

Surrozen has a consensus target price of $42.00, indicating a potential upside of 93.37%. Given Surrozen's stronger consensus rating and higher possible upside, analysts plainly believe Surrozen is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Surrozen	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 30.8% of XBiotech shares are owned by insiders. Comparatively, 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

XBiotech has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

XBiotech has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Surrozen	-4,810.50%	N/A	-154.08%

XBiotech has higher earnings, but lower revenue than Surrozen. XBiotech is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Surrozen	$3.48M	72.46	-$242.03M	-$37.59	N/A

Summary

Surrozen beats XBiotech on 11 of the 16 factors compared between the two stocks.

Get XBiotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIT vs. The Competition

Export

Metric	XBiotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$68.29M	$3.68B	$7.01B	$12.68B
Dividend Yield	N/A	2.18%	2.67%	9.42%
P/E Ratio	-1.72	21.19	26.82	23.95
Price / Sales	N/A	306.01	576.32	115.11
Price / Cash	N/A	155.65	50.60	60.45
Price / Book	0.49	8.00	10.52	6.16
Net Income	-$45.54M	$23.81M	$3.60B	$331.73M
7 Day Performance	-0.87%	-1.22%	-1.34%	-0.92%
1 Month Performance	-2.58%	-1.36%	-0.29%	-2.23%
1 Year Performance	-26.77%	34.77%	18.96%	14.79%

XBiotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIT XBiotech	0.3194 of 5 stars	$2.27 +1.3%	N/A	-26.3%	$68.29M	N/A	N/A	100	High Trading Volume
NAGE Niagen Bioscience	4.3291 of 5 stars	$3.49 +3.6%	$10.50 +200.9%	-64.1%	$268.40M	$129.42M	16.62	120
GALT Galectin Therapeutics	1.7159 of 5 stars	$3.85 -3.8%	$11.00 +185.7%	+22.4%	$263.43M	N/A	N/A	9
CLLS Cellectis	2.6753 of 5 stars	$2.69 +3.5%	$7.00 +160.2%	+51.4%	$260.88M	$79.59M	N/A	290	News Coverage Positive News Upcoming Earnings
ALXO ALX Oncology	2.2481 of 5 stars	$2.05 +6.8%	$4.60 +124.4%	+320.9%	$258.36M	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIT) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XBiotech (XBIT) Competitors

XBIT vs. NAGE, GALT, CLLS, ALXO, and SRZN

How does XBiotech compare to Niagen Bioscience?

Summary

How does XBiotech compare to Galectin Therapeutics?

Summary

How does XBiotech compare to Cellectis?

Summary

How does XBiotech compare to ALX Oncology?

Summary

How does XBiotech compare to Surrozen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XBiotech (XBIT) Competitors

XBIT vs. NAGE, GALT, CLLS, ALXO, and SRZN

How does XBiotech compare to Niagen Bioscience?

Do analysts recommend XBIT or NAGE?

Is XBIT or NAGE more profitable?

Do insiders and institutionals have more ownership in XBIT or NAGE?

Which has better earnings & valuation, XBIT or NAGE?

Does the media favor XBIT or NAGE?

Which has more volatility and risk, XBIT or NAGE?

Summary

How does XBiotech compare to Galectin Therapeutics?

Do insiders & institutionals believe in XBIT or GALT?

Is XBIT or GALT more profitable?

Do analysts recommend XBIT or GALT?

Does the media prefer XBIT or GALT?

Which has more volatility & risk, XBIT or GALT?

Which has better earnings & valuation, XBIT or GALT?

Summary

How does XBiotech compare to Cellectis?

Do analysts recommend CLLS or XBIT?

Is CLLS or XBIT more profitable?

Do institutionals and insiders have more ownership in CLLS or XBIT?

Which has stronger earnings and valuation, CLLS or XBIT?

Does the media favor CLLS or XBIT?

Which has more risk and volatility, CLLS or XBIT?

Summary

How does XBiotech compare to ALX Oncology?

Is ALXO or XBIT more profitable?

Which has better valuation and earnings, ALXO or XBIT?

Do institutionals & insiders have more ownership in ALXO or XBIT?

Does the media favor ALXO or XBIT?

Do analysts prefer ALXO or XBIT?

Which has more risk & volatility, ALXO or XBIT?

Summary

How does XBiotech compare to Surrozen?

Does the media refer more to XBIT or SRZN?

Do analysts rate XBIT or SRZN?

Do insiders & institutionals have more ownership in XBIT or SRZN?

Which has more volatility and risk, XBIT or SRZN?

Is XBIT or SRZN more profitable?

Which has preferable valuation and earnings, XBIT or SRZN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools